PROCEDES DE TRAITEMENT DE PATIENTS PRESENTANT DES MUTATIONS DANS LE DOMAINE EXTRACELLULAIRE DU RECEPTEUR DE FACTEUR DE CROISSANCE EPIDERMIQUE (EGFR) AVEC UNE COMBINAISON DE TROIS ANTICORPS ANTI-EGFR MONOCLONAUX ENTIEREMENT HUMAINS
Provided herein are methods of treating an epidermal growth factor receptor (EGFR) extracellular domain (ECD) mutant cancer in a human patient by administering to the patient an oligoclonal anti-epidermal growth factor receptor (anti-EGFR) antibody combination (e.g., MM-151, comprising a first monoclonal antibody (P1X), a second monoclonal antibody (P2X), and a third monoclonal antibody (P3X),wherein P1X, P2X and P3X are in a 2:2: 1 molar ratio). In one embodiment, the cancer comprises at least one mutation in the extracellular domain of EGFR selected from the group consisting of EGFR R451C, S464L, K467T, G465R, G465E, 1491M, and S492R.
